A5039161763- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CRISPR and Genetic Engineering
- Transgenic Plants and Applications
- SARS-CoV-2 and COVID-19 Research
- Viral Infectious Diseases and Gene Expression in Insects
- Plant Virus Research Studies
- SARS-CoV-2 detection and testing
- Biosensors and Analytical Detection
- Genetics, Bioinformatics, and Biomedical Research
- Bioinformatics and Genomic Networks
- Genomics and Rare Diseases
- Genomic variations and chromosomal abnormalities
- Toxin Mechanisms and Immunotoxins
- Lymphoma Diagnosis and Treatment
- Animal Genetics and Reproduction
- BRCA gene mutations in cancer
- Chronic Myeloid Leukemia Treatments
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- Genetic factors in colorectal cancer
Quest Diagnostics (United States)
2015-2022
Arizona State University
2016-2020
Quest Diagnostics (United Kingdom)
2019
Biopharmaceuticals are a large and fast-growing sector of the total pharmaceutical market with antibody-based therapeutics accounting for over 100 billion USD in sales yearly. Mammalian cells traditionally used monoclonal antibody production, however plant-based expression systems have significant advantages. In this work, we showcase recent advances made plant transient using optimized geminiviral vectors that can efficiently produce heteromultimeric proteins. Two, three, or four...
We previously reported a recombinant protein production system based on geminivirus replicon that yields high levels of vaccine antigens and monoclonal antibodies in plants. The bean yellow dwarf virus (BeYDV) generates massive amounts DNA copies, which engage the plant transcription machinery. However, we noticed disparity between transcript level production, suggesting mRNAs could be more efficiently utilized. In this study, systematically evaluated genetic elements from human, viral,...
The objective of this study was to design and validate a next-generation sequencing assay (NGS) detect BRCA1 BRCA2 mutations. We developed an using random shearing genomic DNA followed by RNA bait tile hybridization NGS on both the Illumina MiSeq Ion Personal Gene Machine (PGM). determined that Reporter software supplied with instrument could not deletions greater than 9 base pairs. Therefore, we alternative alignment variant calling software, Quest Sequencing Analysis Pipeline (QSAP),...
Monitoring new mutations in SARS-CoV-2 provides crucial information for identifying diagnostic and therapeutic targets important insights to achieve a more effective COVID-19 control strategy. Next generation sequencing (NGS) technologies have been widely used whole genome (WGS) of SARS-CoV-2. While various NGS methods reported, one chief limitation has the complexity workflow, limiting scalability. Here, we overcome this by designing laboratory workflow optimized high-throughput studies....
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ORF7a, the ortholog of SARS-CoV is a type I transmembrane protein and plays an important role in virus-host interactions. Deletion variants ORF7a may influence virulence, but only few such isolates have been reported. Here, we report 8 unique deletion 6 to 96 nucleotides length identified from 2,726 clinical specimens collected March 2020.
The use of genetic testing to identify individuals with hereditary cancer syndromes has been widely adopted by clinicians for management inherited risk. objective this study was develop and validate a 34-gene predisposition panel using targeted capture-based next-generation sequencing (NGS). incorporates genes underlying well-characterized syndromes, such as BRCA1 BRCA2 ( BRCA1/2 ), along more recently discovered associated increased We performed validation on 133 unique specimens, including...
Identification of genomic mutations by molecular testing plays an important role in diagnosis, prognosis, and treatment myeloid neoplasms. Next-generation sequencing (NGS) is efficient method for simultaneous detection clinically significant with high sensitivity. Various NGS based in-house developed commercial neoplasm panels have been integrated into routine clinical practice. However, some genes frequently mutated malignancies are particularly difficult to sequence (e.g., CEBPA , CARL...
Abstract Identification of genomic mutations by molecular testing plays an important role in diagnosis, prognosis, and treatment myeloid neoplasms. Next-generation sequencing (NGS) is efficient method for simultaneous detection clinically significant with high sensitivity. However, due to lack standard NGS protocols, the application hematologic malignancies into clinical settings remains limited. We report development validation a 48-gene panel profiling neoplasms including acute leukemia...
e18526 Background: Molecular profiling can help diagnose, classify, and guide treatment of myeloid neoplasms. Next generation sequencing (NGS) is a powerful platform that facilitate identification actionable genetic alterations in multiple genes simultaneously. To serve clinical management needs, we developed validated NGS panel for 47 associated with diagnostic, prognostic, and/or therapeutic utilities each the subclasses neoplasms: acute leukemia (AML, 42 genes), myelodysplastic syndrome...
7033 Background: Partial tandem duplication of the mixed lineage leukemia gene ( MLL-PTD) occurs in about 3% to 5% adult acute myeloid (AML), mostly patients with normal karyotypes, and is associated poor prognosis. Real-time PCR on cDNA or RT-PCR followed by gel electrophoresis are most commonly used methods for detection mutation. However, those require RNA extraction, which not often performed molecular cytogenetic testing next generation sequencing (NGS) AML. In this study, we developed...
Abstract Objectives Identification of genetic alterations by molecular and cytogenetic testing has an important role in the classification, risk stratification, management acute myeloid leukemia (AML). We evaluated a next-generation sequencing (NGS) panel that assesses IDH2, FLT3, NPM1, TP3 38 other genes associated with diagnostic, prognostic, and/or therapeutic utility AML, turnaround time 8 to 14 days, using DNA input 50 ng. Methods In total, 110 patients, 65 males 45 females, at median...
Abstract Background: Identification of genomic variants by molecular testing plays an important role in classification, risk stratification, and management myeloid neoplasms. Next-generation sequencing (NGS) assays that target frequently mutated genes are commonly used clinical settings. Owing to the complexity NGS workflow, performance requirements each assay must be validated for intended use. However, scarcity optimal validation samples challenges efficient assays. We previously reported...
Abstract Background: Hereditary cancer accounts for 5% to 10% of all cancers. In addition sequence variants, copy number variants (CNVs) are a cause inherited syndromes. Next-generation sequencing (NGS) technology enables simultaneous interrogation multiple genes in cost-effective manner. However, accurate CNV detection by NGS remains challenging owing bias and noise that distort the association between read-depth. We previously developed validated an NGS-based algorithm using 18...
Abstract Monitoring new mutations in SARS-CoV-2 provides crucial information for identifying diagnostic and therapeutic targets important insights to achieve a more effective COVID-19 control strategy. Next generation sequencing (NGS) technologies have been widely used whole genome of SARS-CoV-2. While various NGS methods reported, one chief limitation has the complexity workflow, limiting scalability. Here, we overcome this by designing workflow optimized high-throughput studies. The...